Early Prediction by 18F-FDG PET/CT for Progression-Free Survival and Overall Survival in Patients With Metastatic Colorectal Cancer Receiving Third-Line Cetuximab-Based Therapy

被引:23
作者
Liu, Feng-Yuan [1 ,2 ]
Yen, Tzu-Chen [1 ,2 ]
Wang, Jeng-Yi [3 ]
Yang, Tsai-Sheng [4 ]
机构
[1] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Dept Nucl Med, Taoyuan 33305, Taiwan
[2] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Mol Imaging Ctr, Taoyuan 33305, Taiwan
[3] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Div Colon & Rectal Surg,Dept Surg, Taoyuan 33305, Taiwan
[4] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Div Hematol Oncol,Dept Internal Med, Taoyuan 33305, Taiwan
关键词
metastatic colorectal cancer; cetuximab; F-18-FDG PET/CT; response evaluation; survival prediction; POSITRON-EMISSION-TOMOGRAPHY; IMATINIB MESYLATE; PLUS IRINOTECAN; TUMOR RESPONSE; MUTATIONS; METABOLISM; CRITERIA; PERCIST; KRAS;
D O I
10.1097/RLU.0000000000000693
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: In metastatic colorectal cancer (mCRC) with wild-type K-ras, cetuximab-based regimen is an option for third-line therapy. The objective of this study was to assess if early response evaluation by F-18-FDG PET/CT can predict progression-free survival (PFS) and overall survival (OS) in these patients. Patients and Methods: Patients with mCRC going to receive third-line cetuximab-based therapy were enrolled. F-18-FDG PET/CT studies were arranged at baseline and at the ends of the first and fourth weeks of therapy. Treatment response was evaluated with 2 methods: method 1 based on PET response criteria in solid tumors 1.0 and method 2 based on the assumption that an increase in peak tumor metabolism implies nonresponse. Progression-free survival was counted to tumor progression based on the Response Evaluation Criteria in Solid Tumors 1.1 or death. The predictive powers for PFS and OS were analyzed using the Kaplan-Meier method and the log-rank test. Results: Twenty-seven patients were eligible with a median PFS of 5.8 months and a median OS of 9.1 months. Method 2 predicts PFS (P = 0.001) and OS (P < 0.001) at the end of the first week, whereas method 1 does not. Both methods predict PFS and OS at the end of the fourth week. Conclusions: Early response evaluation by F-18-FDG PET/CT predicts PFS and OS in patients with mCRC receiving third-line cetuximab-based therapy. Early therapeutic change may be possible for nonresponsive patients after 1 week of treatment.
引用
收藏
页码:200 / 205
页数:6
相关论文
共 25 条
  • [1] [Anonymous], 2013, GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base
  • [2] Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
    Baldus, Stephan E.
    Schaefer, Karl-L.
    Engers, Rainer
    Hartleb, Dinah
    Stoecklein, Nikolas H.
    Gabbert, Helmut E.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (03) : 790 - 799
  • [3] The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
    Boellaard, Ronald
    Oyen, Wim J. G.
    Hoekstra, Corneline J.
    Hoekstra, Otto S.
    Visser, Eric P.
    Willemsen, Antoon T.
    Arends, Bertjan
    Verzijlbergen, Fred J.
    Zijlstra, Josee
    Paans, Anne M.
    Comans, Emile F. I.
    Pruim, Jan
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (12) : 2320 - 2333
  • [4] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    Choi, Haesun
    Charnsangavej, Chuslip
    Faria, Silvana C.
    Macapinlac, Homer A.
    Burgess, Michael A.
    Patel, Shreyaskumar R.
    Chen, Lei L.
    Podoloff, Donald A.
    Benjamin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1753 - 1759
  • [5] An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
    Chu, Edward
    [J]. CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 1 - 13
  • [6] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) : 337 - 345
  • [7] Systematic Review: Anti-Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer
    Dahabreh, Issa J.
    Terasawa, Teruhiko
    Castaldi, Peter J.
    Trikalinos, Thomas A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 37 - U180
  • [8] Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review
    de Geus-Oei, Lioe-Fee
    Vriens, Dennis
    van Laarhoven, Hanneke W. M.
    van der Graaf, Winette T. A.
    Oyen, Wim J. G.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2009, 50 : 43S - 54S
  • [9] A systematic review of treatment guidelines for metastatic colorectal cancer
    Edwards, M. S.
    Chadda, S. D.
    Zhao, Z.
    Barber, B. L.
    Sykes, D. P.
    [J]. COLORECTAL DISEASE, 2012, 14 (02) : e31 - e47
  • [10] Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
    Findlay, M
    Young, H
    Cunningham, D
    Iveson, A
    Cronin, B
    Hickish, T
    Pratt, B
    Husband, J
    Flower, M
    Ott, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 700 - 708